Haoxi Health Technology (HAO) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
29 Nov, 2025Company overview and business model
Operates as an online marketing solution provider in China, primarily serving healthcare industry advertisers, offering one-stop services including planning, production, placement, and optimization of online ads, especially short video ads.
Revenue is generated through customized marketing solutions delivered via mainstream online platforms such as Toutiao, Douyin, WeChat, and Weibo.
Developed proprietary data analysis software, “Bidding Compass,” to optimize ad placements and improve campaign efficiency.
The company is a Cayman Islands holding entity with operations conducted through its wholly owned PRC subsidiary, Haoxi Beijing.
Financial performance and metrics
For the six months ended December 31, 2023, revenue was $23.50 million with net income of $0.76 million; for the same period in 2022, revenue was $9.16 million and net income $0.45 million.
Fiscal year ended June 30, 2023, revenue was $28.23 million and net income $0.97 million; for 2022, revenue was $16.16 million and net income $0.24 million.
Gross margin for the six months ended December 31, 2023 was 5.11%, down from 7.97% in the prior year period, mainly due to increased competition and customer rebates.
Cash and cash equivalents as of December 31, 2023 were $1.11 million; net cash provided by operating activities for the six months ended December 31, 2023 was $0.30 million.
The company has experienced significant revenue growth but also reports unstable operating revenue and expects continued increases in operating expenses.
Use of proceeds and capital allocation
Net proceeds of approximately $11.4 million are expected from the offering, with 60% allocated to working capital and general corporate purposes, 30% for acquiring or investing in complementary technologies or businesses, and 10% for hiring experienced employees to improve internal controls and compliance.
Plans to invest $2 million in R&D for Bidding Compass and recruit 20 new R&D engineers.
Latest events from Haoxi Health Technology
- All AGM proposals, including share consolidation and director re-elections, passed with over 99% approval.HAO
AGM 202510 Jan 2026 - Registering up to $80M in securities, with strong revenue growth and high PRC regulatory risk.HAO
Registration Filing16 Dec 2025 - Raising up to $80M on Nasdaq, the company targets healthcare marketing in China amid regulatory risks.HAO
Registration Filing16 Dec 2025 - FY2025 revenue fell 32% while net income surged to $3.88M, with ongoing regulatory and supplier risks.HAO
Q4 202412 Dec 2025 - Raising $9.09M to expand healthcare-focused digital marketing in China, but faces regulatory and concentration risks.HAO
Registration Filing29 Nov 2025 - IPO funds will drive growth and tech investment, but regulatory and supplier risks remain high.HAO
Registration Filing29 Nov 2025 - Chinese healthcare-focused ad tech firm seeks $11.4M via Nasdaq unit offering, CEO retains control.HAO
Registration Filing29 Nov 2025 - Rapid revenue growth, high regulatory risk, and CEO control define this complex offering.HAO
Registration Filing29 Nov 2025 - Rapid revenue growth, but high supplier concentration and regulatory risks; $11.4M IPO with warrants.HAO
Registration Filing29 Nov 2025